Abstract
This study was designed to evaluate the efficacy and toxicity of XELIRI plus bevacizumab for the treatment of Japanese patients with unresectable or recurrent colorectal cancer (CRC). This was a multicenter, single-arm, open-label prospective study. The major inclusion criteria were previously untreated unresectable or recurrent CRC, presence of measurable lesions, ≥20 years of age, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients received bevacizumab (7.5 mg/kg on day 1) and XELIRI (irinotecan 200 mg/m(2) on day 1 plus capecitabine 800 mg/m(2) b.i.d. on days 1-14) every 3 weeks. The primary endpoint was the objective tumor response rate. A total of 36 patients were enrolled in this study from July 2011 to September 2012. One patient did not fulfill the eligibility criteria and one patient withdrew their consent before the start of the treatment protocol. The confirmed objective response rate was 58.8% (95% CI 35.1-70.2%). The median progression-free survival was 9.6 months (95% CI 5.1-11.1 months) and the median overall survival was 23.1 months (95% CI 11.3-36.7 months). The grade ≥3 adverse events that were frequently encountered in this study were neutropenia (31.4%), leukop...Continue Reading
References
Apr 1, 2000·Lancet·J Y DouillardP Rougier
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P M HoffR Wong
Nov 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Van CutsemUNKNOWN Xeloda Colorectal Cancer Study Group
Sep 5, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M TewesU Vanhoefer
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts
Aug 28, 2004·Oncology·Se Hoon ParkJae Hoon Lee
Jan 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M M BornerUNKNOWN Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland
Jun 9, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D W ReaC J A Punt
May 2, 2007·The Oncologist·Maartje LosEmile E Voest
May 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean-François CôtéMarc Ychou
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles S FuchsJosé Barrueco
Jul 24, 2010·AJR. American Journal of Roentgenology·Mizuki NishinoAnnick D Van den Abbeele
Jun 9, 2012·Pharmacogenomics·Mafalda M DiasMichael J Sorich
Jan 29, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M DucreuxT Conroy
Mar 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W SchmiegelU Graeven
Mar 27, 2013·The Pharmacogenomics Journal·X LiuW Xu
Oct 5, 2014·The Oncologist·Yasuo HamamotoYasuhide Yamada
Dec 30, 2015·International Journal of Clinical Oncology·Yoshinori MiyataMitsuaki Manabe
Citations
Dec 8, 2017·Journal of Cellular Physiology·Sisi LinAlexandr V Bazhin
Aug 29, 2018·Cancer Science·Wenyue LiuFang Zhou
Jul 28, 2018·The Oncologist·Goro NakayamaYasuhiro Kodera
Jul 25, 2019·International Journal of Clinical Oncology·Kosuke HiroseMasaki Mori
May 8, 2019·International Journal of Clinical Oncology·Shun SasakiYoshihiko Maehara